Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. Jerkeman

Targeting of B-Cell Receptor Signalling in B-Cell Malignancies

Journal of Internal Medicine

Internal Medicine

2017

English

Young High Risk Patients With Diffuse Large B-Cell Lymphoma Including BCL-2/Myc Double Hit Lymphomas Benefit From Dose-Dense Immunochemotherapy With Early CNS Prophylaxis

Hematological Oncology

English

Early Progression of Mantle Cell Lymphoma Depicts a High-Risk Disease With Poor Response to Subsequent Therapies and a Dismal Outcome

Hematological Oncology

English

Bortezomib Prevents Development of Cytarabine Resistance in a Mantle Cell Lymphoma in Vitro Model

Hematological Oncology

English

Mortality Rates Remain Increased in Young Patients With Classical Hodgkin Lymphoma Even After Years in Remission: Results From a Nordic Lymphoma Group Study

Hematological Oncology

English

Phase 1/2a Clinical Trials of Bi-1206, a Monoclonal Antibody to Fcγriib, Administered as a Single Agent or in Combination With Rituximab in Subjects With B-Cell Malignancies

Hematological Oncology

English

Serum Biomarkers Are Associated With Treatment Response in Relapsed Mantle Cell Lymphoma

Hematological Oncology

English

Outcome Prediction in Diffuse Large B-Cell Lymphoma Can Be Greatly Improved by Alternative Use of Clinical Information: A Nordic Lymphoma Group Study

Hematological Oncology

English

Evolution of Clonal Hematopoiesis in Mantle Cell Lymphoma Patients Before, During, and After Induction Chemotherapy and Autologous Stem Cell Transplantation

Hematological Oncology

English

Dose-Dense Chemoimmunotherapy and CNS Prophylaxis in Patients With High-Risk Dlbcl: A Comparison of Nordic Cry-04 and Chic Studies

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. Jerkeman

Targeting of B-Cell Receptor Signalling in B-Cell Malignancies

Young High Risk Patients With Diffuse Large B-Cell Lymphoma Including BCL-2/Myc Double Hit Lymphomas Benefit From Dose-Dense Immunochemotherapy With Early CNS Prophylaxis

Early Progression of Mantle Cell Lymphoma Depicts a High-Risk Disease With Poor Response to Subsequent Therapies and a Dismal Outcome

Bortezomib Prevents Development of Cytarabine Resistance in a Mantle Cell Lymphoma in Vitro Model

Mortality Rates Remain Increased in Young Patients With Classical Hodgkin Lymphoma Even After Years in Remission: Results From a Nordic Lymphoma Group Study

Phase 1/2a Clinical Trials of Bi-1206, a Monoclonal Antibody to Fcγriib, Administered as a Single Agent or in Combination With Rituximab in Subjects With B-Cell Malignancies

Serum Biomarkers Are Associated With Treatment Response in Relapsed Mantle Cell Lymphoma

Outcome Prediction in Diffuse Large B-Cell Lymphoma Can Be Greatly Improved by Alternative Use of Clinical Information: A Nordic Lymphoma Group Study

Evolution of Clonal Hematopoiesis in Mantle Cell Lymphoma Patients Before, During, and After Induction Chemotherapy and Autologous Stem Cell Transplantation

Dose-Dense Chemoimmunotherapy and CNS Prophylaxis in Patients With High-Risk Dlbcl: A Comparison of Nordic Cry-04 and Chic Studies